Background: Durability of response is a clinically relevant dimension of the treatment effect in randomized clinical trials; it is often measured by comparing among the responders the duration of response between the treatment arms. However, since the comparison groups are defined by response (a post-randomization event), it is subject to analysis-by-responder bias, especially if the proportion of responders differs between the arms.
Introduction
Most cancer treatments do not work for all patients. Therefore, there is a great potential for personalized medicine with agents targeted to specific molecularly defined tumor subgroups. However, in situations where there is not a biomarker that can identify patients who will be helped by the new treatment, an intent-to-treat analysis of a traditional broad-eligibility randomized clinical trial (RCT) can still be used to estimate the average clinical benefit of the new treatment relative to the standard treatment over the whole population (perhaps with specialized procedures to account for only some patients benefiting [1, 2] ). Even though this addresses the clinical question (given the lack of a predictive biomarker), there is frequently scientific interest in whether the new treatment provides an especially strong benefit in the subgroup of patients who are responsive to it. It is well known that inferring that a new treatment works because responders live longer than non-responders in a single-arm trial is inappropriate: response may be a marker for good prognosis patients and the longer survival of responding patients may have nothing to do with the relative effectiveness of the new treatment [3] .
In an RCT, one has the opportunity of comparing the longterm clinical outcomes between the experimental and standard treatment arms for the responding patients. This has been done frequently in trials of immunotherapy in solid tumors (e.g. reference [4] ) and for more general treatments in trials in hematologic malignancies (e.g. reference [5] ). For example, in the CheckMate-057 trial of nivolumab versus docetaxel in advanced non-squamous non-small-cell lung cancer, it was noted the median duration of response was 17.2 month in the 56 responders to nivolumab and 5.6 months in the 36 responders to docetaxel [6] . Although this is a large difference, we will argue below that it probably underestimates the benefit of the nivolumab in the responding group because of analysis-by-responder bias.
This article considers exploratory approaches to assessing treatment efficacy in responders that are less subject to analysisby-responder bias due to differing response rates in the treatment arms. As described in the next section, the idea is to construct comparably sized groups of patients in each of the treatment arms for whom long-term outcomes can be compared. We then present two examples reanalyzing published duration-ofresponse comparisons.
Methods
We first present a very small hypothetical example to show how analysisby-responder bias arises. We then demonstrate methods to minimize this bias by constructing comparable equally sized subgroups of responders (or near responders) in the treatment arms. This can be done in two ways: by subtracting some 'barely responding' cases from the arm with more responders, or by adding some 'near responding' cases to the arm with fewer responders.
Hypothetical example of analysis-by-responder bias
Suppose the trial had 30 patients in each of the control and experimental arms (Figure 1) , with the long-term clinical outcome being survival and with the tumor response defined by partial response (PR) using RECIST criteria [7] (at least a 30% decrease in the sum of diameters of target lesions). There are 6 responders in the control arm ( Figure 1A ) and 15 responders in the experimental arm ( Figure 1B) . Note that (i) for each arm, the survival is correlated with change in tumor size, but not perfectly, (ii) the distribution of change in tumor-size percentages is shifted lower for the experimental arm versus the control arm, and (iii) the survival time distributions are identical in the control and experimental arms. The last point is consistent with the experimental and control treatments being equally effective for all of the patients. However, if one compares the survival for the responding patients only, one sees that the experimental arm survival is worse (an average of 13.3 months for the responding experimental-arm patients versus 15.6 months for the responding control-arm patients). Although this is true, it would be wrong to assume that this means the experimental treatment is worse than the control treatment for any set of patients. This is an example of analysis-byresponder bias. It is due to the use of a post-randomization measurement to determine who is being analyzed in each treatment group, which, in this case, leads to a prognostic imbalance between the two responder groups (as well as an imbalance in the number of patients).
Subtraction method
Continuing with the hypothetical data, one would want to identify and remove the nine responding patients in the experimental arm that would have been least likely to have a response if they had been treated with the control treatment. One approach would be to subtract the nine experimental-arm responding patients who had the worst clinical outcomes, e.g. the shortest survival. This would be a very anti-conservative approach in that it would maximize any benefit seen for the experimental treatment; after all, the comparison is with the six responding patients in the control arm and not the six patients in the control arm with best survival. The approach we suggest is to subtract from the responding patients on the experimental arm the nine patients who had the weakest tumor responses; we subtract the nine responding experimental-arm patients with the least tumor shrinkage (when compared with pre-randomization baseline values). For our hypothetical data ( Figure 2 ), we see that this would correctly conclude that the experimental treatment offers no survival advantage to the patients who responded in the control arm (an average of 15.6 months with either treatment). Note that our approach is agnostic to the particular definition of response that is used, and can be used, e.g. with new immune-related response criteria [8] .
The choice of time-to-event outcome can be progression/death, in which case the comparison between the constructed responding subgroups in the treatment arms could be for duration of response (time from response to progression/death) or progression-free survival (time from randomization to progression/death, PFS). the baseline measurement [7] .) One could also compare the overall survival (time from randomization to death) between the constructed responding subgroups. The conclusions of a subtraction analysis are for the responders in the control arm versus a comparably sized group of best responders in the experimental arm.
Addition method
With the hypothetical data in Figure 1 , for the proposed addition method, one would want to identify an additional nine patients in the control arm who would have responded if given the experimental treatment. The non-responding control-arm patients are ranked by their maximum tumor-burden decrease, with nine patients with the most tumor-burden reduction added to the six responders to form the control-arm comparison group (Figure 3) . We see that the addition method would correctly conclude that the experimental treatment offers no survival advantage to the patients who responded in the experimental arm (an average of 13.3 months with either treatment).
With the addition method, the beginning time of the time-to-event outcome should be the time of randomization, as evaluating duration of response is not possible when not all the patients being compared have had a response. The conclusions of an addition analysis are for the responders in the experimental arm versus a comparably sized group of responders and near responders in the control arm. 
Additional considerations for both methods
In the example above, we assumed that the randomization was 1 : 1 (30 patients per arm). If the randomization ratio had been different (e.g. 2 : 1), the subtraction and addition methods would subtract and add patients so that the proportion of responders would be the same in the comparison groups.
Although the example assumed that there was no treatment benefit for the experimental arm, the methods work more generally. For example, suppose instead the experimental treatment increases the survival for every patient by 50% over the control treatment. (That is, the horizontal scale in Figures 1B, 2B , and 3B went from 0 to 36 months instead of from 0 to 24 months.) Then comparing the survival among responders would underestimate the 50% improvement offered by the experimental treatment, whereas the subtraction and addition methods would estimate the 50% improvement correctly. We note that this hypothetical data example was chosen to demonstrate how responder-by-analysis arises and how the proposed methods would work. The relationships between tumor shrinkage, survival, and treatment are more complex in real data. Therefore, in practice the proposed methods should be viewed as exploratory analyses.
With real data, not all patients will have progressed at the time of analysis. Standard survival analysis methods, which account for censored Figure 4A ).
events, can be used to analyze the progression-free survival data in the identified subgroups. Note that sufficient follow-up will be required to be able to evaluate the maximum tumor-burden decrease for each patient, as this is being used to determine which patients are in the analyzed subgroups.
In some applications, such as in the S1117 trial discussed below, there are a lower proportion of responders in the experimental arm than the control arm. In these situations, the comparison between the arms of long-term outcomes (like duration of response or survival) will overestimate the benefits of the experimental treatment if the analysis is restricted to the responders; the subtraction and addition methods should help with this bias.
Results

CheckMate-057 trial
For the 56 nivolumab and 36 docetaxel responding patients, Figures 4A and 5A display the Kaplan-Meier plots for the duration of response (hazard ratio (HR) ¼ 0.28; 95% CI: 0.16, 0.49) and PFS (HR ¼ 0.29; 95% CI: 0.17, 0.51), respectively. Since there were more responders in the nivolumab arm, we expect that these hazard ratios underestimate the benefit of the nivolumab. Using the subtraction method, we remove from the analysis the 20 nivolumab responding patients who had the least tumor burden shrinkage during their follow-up. The resulting curves are given in Figures 4B and 5B for duration of response (HR ¼ 0.17; 95% CI: 0.09, 0.34) and PFS (HR ¼ 0.19; 95% CI: 0.10, 0.38), respectively. (As the proposed methods are exploratory, the confidence intervals should be interpreted as providing an estimate of the variability of the hazard ratios and not having formal inferential content.) Using the addition method, we add to the analysis the 20 docetaxel non-responding patients who had the most tumor burden shrinkage during their follow-up. The resulting PFS curves are given in Figure 5C (HR ¼ 0.24; 95% CI: 0.14, 0.39). As expected, and consistent with the estimated hazard ratios, the differences between the docetaxel and nivolumab curves in Figures 4 and 5 using either the subtraction or addition methods is greater than when comparing the responders in each treatment arm.
S1117 trial
The SWOG S1117 trial was of azacitidine, azacitidine þ vorinostat, and azacitidine þ lenalidamide in myelodysplastic syndrome and chronic myelomonocytic leukemia. We focus here on the azacitidine and azacitidine þ vorinostat treatment arms; it was noted the median duration of response was 18 months in the 25 responders in the azacitidine þ vorinostat group and 10 months in the 35 responders in the azacitidine group [9] . The proportion of responders was 27% for the azacitidine þ vorinostat combination treatment was less than the 38% response rate seen for the azacitidine alone. The Kaplan-Meier plots for the duration of response for the responders are given in Figure 6A ; the HR is 0.77 (95% CI: 0.43, 1.36). As there were more responders in the azacitidine (control) arm, we expect this hazard ratio overestimates the benefit of the combination treatment.
To apply the subtraction method, we need to rank the 35 responders in the azacitidine group-based and select the 10 with the 'weakest' responses for removal from the group. As response was defined in this trial as complete response, PR, or hematologic improvement [10] , this selection is not straightforward and is described in the supplementary materials, available at Annals of Oncology online. Figure 6B displays the duration of response for the two treatment groups using the subtraction method. As expected, the azacitidine curve has moved up; the hazard ratio is 0.91 (95% CI: 0.50, 1.67). Figure 7A and B displays the PFS curves for all responders (HR ¼ 0.76, 95% CI: 0.43, 1.34) and for the subtraction method (HR ¼ 0.90, 95% CI: 0.49, 1.65), Figure 5A ) and (C) addition method (red curve is a copy of the docetaxel curve from Figure  5A ).
respectively. We believe that the subtraction method curves ( Figures 6B and 7B) give a better representation of efficacy of the combination treatment in the patients responding to the combination treatment than the curves with all the responding patients ( Figures 6A and 7A ).
Discussion
In the single-arm setting, concerns about comparing outcomes of responders and non-responders fall into two categories. The first, and the one which is being addressed by this paper in the RCT setting, is that response is potentially identifying patients who had a better prognosis at baseline. The second concern raised in the single-arm setting is guarantee-time bias: patients must live long enough to have a response, so responders will tend to live longer than non-responders regardless of the effectiveness of therapies [3] . In the single-arm setting, there are approaches to eliminating guarantee-time bias, e.g. using landmark analyses or treating response as a time-dependent covariate. (These approaches do not help with the fact the response may be a Figure 6 . Duration of response for myelodysplastic syndrome and chronic myelomonocytic leukemia patients treated with azacitidine (blue curves) versus azacitidine þ vorinostat (yellow curves) in the S1117 trial. (A) All responders and (B) subtraction method (red curve is a copy of the azacitidine curve from Figure 6A ).
marker for better-prognosis patients [11] .) Note that using the addition or subtraction methods described in this paper, there is not a major issue with guarantee-time bias: for the subtraction method, patients being compared are all responders, and for the addition method, all patients being compared are all responders or have good tumor shrinkage. Therefore, patients who die early are not relevant to the subgroups being considered. The exploratory analyses of treatment effects in responders described here are not meant to substitute for the use of (pre-treatment) biomarkers to identify patients who are most likely to benefit from the experimental treatment. If such a biomarker were definitively known, one could restrict the eligibility for the RCT to biomarker-positive patients. Even if the pre-trial evidence that a biomarker is predictive is not strong enough to restrict eligibility to the trial, it may be sufficient to formally incorporate the biomarker into the trial design [2] . Nor are the analyses here intended to be a definitive comparison between the treatment arms that incorporates duration of response in some Figure 7. Progression-free survival for myelodysplastic syndrome and chronic myelomonocytic leukemia patients treated with azacitidine (blue curves) versus azacitidine þ vorinostat (yellow curves) in the S1117 trial. (A) All responders and (B) subtraction method (red curve is a copy of the azacitidine curve from Figure 7A ).
manner but analyzes all randomized patients. For example, one could perform a duration of response analysis where nonresponding patients are assigned a duration of zero [12] ; other more sophisticated approaches are available to compare all randomized patients [13] or to understand the relationship between tumor growth patterns and treatment [14] . Instead, we assume that in a given setting, tumor shrinkage has prognostic value regardless of the treatment received. This assumption is used to construct the simple exploratory approaches of using tumor measurements to achieve comparable subgroups to help reduce some of the analysis-by-responder bias in comparing the responding subgroups of treatment arms. The proposed exploratory analyses could be useful in making drug development decisions: following a trial that demonstrated only marginal overall benefit (or a benefit that failed to meet a formal significance threshold) the proposed approaches may help in deciding whether more effort should be directed toward identifying a subset of likely responders to an experimental treatment.
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